Sara Cristina Monteiro Gonçalves De Oliveira *

Autora invitada por SIIC

O ESTADO DA ARTE

INTERACÇÕES MEDICAMENTOSAS ENTRE A METADONA E OS ANTI-RETROVIRAIS

Têm sido documentadas inúmeras interacções medicamentosas entre a metadona e os ARV. Contudo, a eficácia dos ARV foi comprovada em doentes infectados com VIH, pelo que, ponderadas as possíveis interacções medicamentosas e a necessidade de ajuste da dose dos fármacos, o início do tratamento não deve ser adiado.

*Sara Cristina Monteiro Gonçalves De Oliveira
describe para SIIC los aspectos relevantes de su trabajo
INTERACÇÕES MEDICAMENTOSAS ENTRE A METADONA E OS ANTI-RETROVIRAIS
Institución principal de la investigación
*Centro Hospitalar de Vila Nova de Gaia/espinho, Vila Nova De Gaia, Portugal
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
Bruce, R.D., Altice, F.L., Gourevitch, M.N., Friedland, G.H. (2006). “Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice”. J Acquir Immune Defic Syndr, 41, 563-572. Faragon, J.J., Piliero, P.J. (2003). “Drug interactions associated with HAART: Focus on treatments for addiction and recreational drugs”. AIDS Read, 13(9). Ferrari, A., Coccia C., Bertolini, A., Stermieri, E. (2004). “Methadone-metabolism, pharmacokinetics and interactions.” Pharmacological Research, 50, 551-559. Friedland, G., Andrews, L., Schreibman, T., et al. (2005). “Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction”. AIDS, 19(15), 1635-1641. Hendrix, C.W., Wakeford, J., Wire, M.B., et al. (2004). “Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects”. Pharmacotherapy. 24(9). Kharasch, E.D., Bedynek, P.S., Park, S., Whittington, D., Walker, A., Hoffer, C. (2008). “Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance”. Clinical Pharmacology & Therapeutics, 84(4), 497-505. Kharasch, E.D., Bedynek, P.S., Walker, A., Whittington, D., Hoffer, C. (2008). “Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. ritonavir effects on CYP3A and P-glycoprotein activities”. Clinical Pharmacology & Therapeutics, 84(4), 506-512. Kharasch, E.D., Hoffer, C., Whittington, D., Sheffels, P. (2004). “Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone”. Clinical Pharmacology & Therapeutics, 76(3), 250-269. Kharasch, E.D., Mitchell, D., Coles, R., Blanco R. (2008). “Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir”. Antimicrobial Agents and Chemotherapy, 52(5), 1663-1669. Kharasch, E.D., Walker, A., Whittington, D., Hoffer, C., Bedynek, P.S. (2009). “Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity”. Drug and alcohol Dependence, 101, 158-168. Lert, F., Kazatchkine, M.D. (2007). “Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview”. International Journal of Drug Policy, 18, 255-261. Loughlin, A.M., Schwartz, R., Strathdee, S.A. (2004). “Prevalence and correlates of HCV infection among methadone maintenance attendees: implications for HCV treatment.” International Journal of Drug Policy, 15, 93-101. McCance-Katz, E.F., Rainey, P.M., Jatlow, P., Friedland, G. (1998). “Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)”. J Acquir Immune Defic Syndr, 18, 435-443. Rainey, P.M., Friedland, G., McCance-Katz, E.F., et al (2000). “Interaction of methadone with didanosine and stavudine”. J Acquir Immune Defic Syndr, 24, 241–248. Smith, P.F., Kearney, B.P., Liaw, S., et al (2004). “Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone”. Pharmacotherapy, 24(8). Stine, S.M., Kosten, T.R. (1997). “Methadone dose in the treatment of opiate dependence”. Medscape Psychiatry & Mental Health eJournal, 2(6). Vocci, F.J., Acri,J., Elkashef, A. (2005). “Medication development for addictive disorders: The state of the science”. Am J Psychiatry, 162, 1432-1440. Weber, R., Huber, M., Rickenbach, et al (2009) “Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: The Swiss HIV Cohort Study”. HIV Medicine, 10(7), 407-416. Wong, K., Lee, S., Lim, W. Low, H. (2003). “Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users”. Journal of Substance Abuse Treatment, 24, 233-239.